Neuromyotonia: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{{Short description|Rare neurological disorder affecting peripheral nerves}}
{{Use dmy dates|date=March 2022}}
{{cs1 config |name-list-style=vanc |display-authors=6}}


'''Neuromyotonia''' ('''NMT''') is a form of peripheral nerve hyperexcitability that causes spontaneous [[muscle|muscular]] activity resulting from repetitive motor unit action potentials of peripheral origin. The prevalence of NMT is unknown but 100–200 cases have been reported so far.<ref name="orpha">{{cite web|title = Isaac syndrome|url = http://www.orpha.net/consor/cgi-bin/Disease_Search.php?data_id=11619|publisher = OrphaNet|year = 2013|accessdate = 30 November 2015}}</ref>
{{Infobox medical condition
| name = Neuromyotonia
| synonyms = Isaacs' Syndrome
| image =
| caption =
| field = [[Neurology]], [[Neurophysiology]]
| symptoms = Muscle cramps, stiffness, fasciculations, hyperhidrosis, myoclonic jerks
| complications = Morvan's syndrome (rare)
| onset = Typically between ages 15–60
| duration = Chronic, but treatable
| causes = [[Autoimmune disease]], [[paraneoplastic syndrome]], [[genetic disorder]]
| diagnosis = Clinical evaluation, [[electromyography]] (EMG), antibody tests, CT scan
| treatment = [[Anticonvulsants]], [[plasma exchange]], [[IVIg]], [[immunosuppressants]]
| prognosis = Good with treatment
| frequency = Rare (100–200 cases reported worldwide)<ref name="orpha">{{cite web|title = Isaac syndrome|url = http://www.orpha.net/consor/cgi-bin/Disease_Search.php?data_id=11619|publisher = OrphaNet|year = 2013|accessdate = 30 November 2015}}</ref>
}}
 
'''Neuromyotonia''' ('''NMT'''), also known as '''Isaacs' Syndrome''', is a rare neurological disorder characterized by peripheral nerve hyperexcitability, leading to continuous muscle activity. It results from repetitive motor unit action potentials of peripheral origin. The exact prevalence is unknown, but 100–200 cases have been reported worldwide.<ref name="orpha"/>
 
== Signs and Symptoms ==
Neuromyotonia manifests as a diverse set of neuromuscular symptoms, including:
* Muscle cramps and stiffness
* Myotonia-like symptoms (slow muscle relaxation)
* Walking difficulties
* Hyperhidrosis (excessive sweating)
* Myokymia (muscle quivering)
* Fasciculations (muscle twitching)
* Fatigue and exercise intolerance
* Myoclonic jerks (sudden muscle movements)


== Signs and symptoms ==
Symptoms most commonly affect the calves, legs, trunk, and sometimes the face and neck, though other body parts may be involved. Symptom severity can range from mild discomfort to debilitating muscle activity. Up to one-third of patients also experience sensory disturbances.
NMT is a diverse disorder. As a result of muscular hyperactivity, patients may present with muscle cramps, stiffness, [[myotonia]]-like symptoms (slow relaxation), associated walking difficulties, [[hyperhidrosis]] (excessive sweating), [[myokymia]] (quivering of a muscle), [[fasciculation]]s (muscle twitching), fatigue, exercise intolerance, [[myoclonic jerk]]s and other related symptoms. The symptoms (especially the stiffness and fasciculations) are most prominent in the calves, legs, trunk, and sometimes the face and neck, but can also affect other body parts. NMT symptoms may fluctuate in severity and frequency. Symptoms range from mere inconvenience to debilitating. At least a third of people also experience sensory symptoms.


== Causes ==
== Causes ==
The three causes of NMT are:{{citation needed|date=November 2015}}
Neuromyotonia is categorized into three types based on etiology:{{citation needed|date=November 2015}}
# Acquired
# Acquired (most common, up to 80% of cases)
# [[Paraneoplastic syndrome|Paraneoplastic]]
# Paraneoplastic (associated with certain cancers)
# Hereditary
# Hereditary (genetic mutations)


The acquired form is the most common, accounting for up to 80 percent of all cases and is suspected to be autoimmune-mediated, which is usually caused by [[antibody|antibodies]] against the neuromuscular junction.
The acquired form is believed to be autoimmune-mediated, typically involving antibodies targeting voltage-gated potassium channels (VGKCs) on motor nerves, leading to excessive nerve firing. NMT often coexists with other autoimmune diseases, such as:
* [[Myasthenia gravis]]
* [[Lambert-Eaton myasthenic syndrome]]
* [[Paraneoplastic cerebellar degeneration]]
* [[Paraneoplastic limbic encephalitis]]


The exact cause is unknown. However, autoreactive antibodies can be detected in a variety of peripheral (e.g. [[myasthenia gravis]], [[Lambert-Eaton myasthenic syndrome]]) and central nervous system (e.g. [[paraneoplastic cerebellar degeneration]], [[paraneoplastic limbic encephalitis]]) disorders. Their causative role has been established in some of these diseases but not all. Neuromyotonia is considered to be one of these with accumulating evidence for [[autoimmune disorder|autoimmune origin]] over the last few years. Autoimmune neuromyotonia is typically caused by antibodies that bind to [[potassium channels]] on the [[motor nerve]] resulting in continuous/hyper-excitability.  Onset is typically seen between the ages of 15–60, with most experiencing symptoms before the age of 40.<ref name="NINDS" /> Some neuromyotonia cases do not only improve after [[blood plasma|plasma]] exchange but they may also have antibodies in their [[blood plasma|serum]] samples against [[voltage-gated potassium channel]]s.<ref>{{cite journal |author=Maddison P |title=Neuromyotonia |journal=Clinical Neurophysiology |volume=117 |issue=10 |pages=2118–27 |year=2006 |pmid=16843723 |doi=10.1016/j.clinph.2006.03.008}}</ref> Moreover, these antibodies have been demonstrated to reduce potassium channel function in neuronal cell lines.
Some cases improve with plasma exchange, suggesting an autoimmune basis. Onset generally occurs between ages 15–60, with most cases appearing before 40.<ref name="NINDS" />


== Diagnosis ==
== Diagnosis ==
Diagnosis is clinical and initially consists of ruling out more common conditions, disorders, and diseases, and usually begins at the general practitioner level. A doctor may conduct a basic neurological exam, including coordination, strength, reflexes, sensation, etc. A doctor may also run a series of tests that include blood work and MRIs.
Diagnosis of neuromyotonia involves ruling out more common conditions and performing specialized neurological testing.


From there, a patient is likely to be referred to a neurologist or a neuromuscular specialist. The neurologist or specialist may run a series of more specialized tests, including needle [[electromyography]] EMG/ and [[nerve conduction studies]] (NCS) (these are the most important tests), chest CT (to rule out paraneoplastic) and specific blood work looking for voltage-gated potassium channel antibodies, acetylcholine receptor antibody, and serum immunofixation, TSH, ANA ESR, EEG etc. Neuromyotonia is characterized electromyographically by doublet, triplet or multiplet single unit discharges that have a high, irregular intraburst frequency.  [[Fibrillation]] potentials and [[fasciculations]] are often also present with [[electromyography]].<ref name="Newsom-Davis">{{cite journal|vauthors=Newsom-Davis J, Mills KR |title=Immunological associations of acquired neuromyotonia (Isaacs' syndrome)|journal=Brain|year=1993|volume=116|issue=2|pages=453–469|doi=10.1093/brain/116.2.453|pmid=8461975}}</ref>
Clinical Evaluation
* Neurological examination (strength, reflexes, coordination)
* Blood tests for voltage-gated potassium channel (VGKC) antibodies
* MRI and CT scans (to rule out tumors or other disorders)


Because the condition is so rare, it can often be years before a correct diagnosis is made.
Electromyography (EMG) and Nerve Conduction Studies (NCS)
Neuromyotonia is characterized by:<ref name="Newsom-Davis">{{cite journal|vauthors=Newsom-Davis J, Mills KR |title=Immunological associations of acquired neuromyotonia (Isaacs' syndrome)|journal=Brain|year=1993|volume=116|issue=2|pages=453–469|doi=10.1093/brain/116.2.453|pmid=8461975}}</ref>
* Continuous muscle fiber activity
* Doublet, triplet, or multiplet single unit discharges
* High-frequency bursts
* Fibrillations and fasciculations


NMT is not fatal and many of the symptoms can be controlled. However, because NMT mimics some symptoms of motor neuron disease (ALS) and other more severe diseases, which may be fatal, there can often be significant anxiety until a diagnosis is made. In some rare cases, acquired neuromyotonia has been misdiagnosed as amyotrophic lateral sclerosis (ALS)<ref>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688–700.</ref> particularly if fasciculations may be evident in the absence of other clinical features of ALS. However, fasciculations are rarely the first sign of ALS as the hallmark sign is weakness.<ref>Hirota N, Eisen A, Weber M. Complex fasciculations and their origin in amyotrophic lateral sclerosis and Kennedy’s disease. Muscle Nerve 2000; 23: 1872–5.</ref> Similarly, multiple sclerosis has been the initial misdiagnosis in some NMT patients. In order to get an accurate diagnosis see a trained neuromuscular specialist.
Because neuromyotonia is rare, misdiagnosis is common, often being confused with:
* Amyotrophic lateral sclerosis (ALS) (especially in cases with fasciculations)<ref>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688–700.</ref>
* Multiple sclerosis (MS)
* Benign Fasciculation Syndrome (BFS) or Cramp Fasciculation Syndrome (CFS)


People diagnosed with Benign Fasciculation Syndrome or Enhanced Physiological Tremor may experience similar symptoms as NMT, although it is unclear today whether BFS or EPT are weak forms of NMT.
== Types ==
There are three main types of neuromyotonia:{{citation needed|date=November 2015}}
* Chronic – Progressive but manageable with treatment.
* Monophasic – Symptoms resolve within several years, often after infection or allergic reaction.
* Relapsing-remitting – Periods of symptom flare-ups and remission.


=== Types ===
Peripheral Nerve Hyperexcitability Spectrum
There are three main types of NMT:{{citation needed|date=November 2015}}
Neuromyotonia is part of a spectrum of peripheral nerve hyperexcitability syndromes, which includes:<ref>{{Cite journal |doi = 10.1093/brain/awf178|pmid = 12135978|title = Phenotypic variants of autoimmune peripheral nerve hyperexcitability|journal = Brain|volume = 125|issue = 8|pages = 1887–1895|year = 2002|last1 = Hart|first1 = I. K.|last2 = Maddison|first2 = P.|last3 = Newsom-Davis|first3 = J.|last4 = Vincent|first4 = A.|last5 = Mills|first5 = K. R.|doi-access = free}}</ref>
* Chronic
1. Benign Fasciculation Syndrome (BFS) (mildest form)
* Monophasic (symptoms that resolve within several years of onset; postinfection, postallergic)
2. Cramp Fasciculation Syndrome (CFS)
* Relapsing Remitting
3. Neuromyotonia (NMT)
4. Morvan's syndrome (most severe, associated with hallucinations, memory loss, and insomnia)


=== Peripheral nerve hyperexcitability ===
== Treatment ==
Neuromyotonia is a type of peripheral nerve hyperexcitability. Peripheral nerve hyperexcitability is an umbrella diagnosis that includes (in order of severity of symptoms from least severe to most severe) [[benign fasciculation syndrome]], [[cramp fasciculation syndrome]], [[neuromyotonia]] and [[morvan's syndrome]]. Some doctors will only give the diagnosis of peripheral nerve hyperexcitability as the differences between the three are largely a matter of the severity of the symptoms and can be subjective. However, some objective EMG criteria have been established to help distinguish between the three.
There is no known cure for neuromyotonia, but treatment can control symptoms.


Moreover, the generic use of the term ''peripheral nerve hyperexcitability syndromes'' to describe the aforementioned conditions is recommended and endorsed by several prominent researchers and practitioners in the field.<ref>{{Cite journal |doi = 10.1093/brain/awf178|pmid = 12135978|title = Phenotypic variants of autoimmune peripheral nerve hyperexcitability|journal = Brain|volume = 125|issue = 8|pages = 1887–1895|year = 2002|last1 = Hart|first1 = I. K.|last2 = Maddison|first2 = P.|last3 = Newsom-Davis|first3 = J.|last4 = Vincent|first4 = A.|last5 = Mills|first5 = K. R.|doi-access = free}}</ref>
First-Line Treatments
* Anticonvulsants – Phenytoin and carbamazepine reduce nerve hyperactivity.
* Plasma Exchange (Plasmapheresis) and IVIg – Effective in autoimmune cases.<ref name="NINDS">{{cite web|title=NINDS Isaac's syndrome information page|url=http://www.ninds.nih.gov/disorders/isaacs_syndrome/isaacs_syndrome.htm|accessdate=8 May 2011|author=National Institute of Neurological Disorders and Stroke.|year=2010|archive-url=https://web.archive.org/web/20110412032703/http://www.ninds.nih.gov/disorders/isaacs_syndrome/isaacs_syndrome.htm|archive-date=12 April 2011|url-status=dead}}</ref>
* Immunosuppressants – Prednisone or other corticosteroids help in autoimmune cases.


== Treatments ==
Other Therapies
There is no known cure for neuromyotonia, but the condition is treatable. [[Anticonvulsants]], including [[phenytoin]] and [[carbamazepine]], usually provide significant relief from the stiffness, muscle spasms, and pain associated with neuromyotonia. Plasma exchange and IVIg treatment may provide short-term relief for patients with some forms of the acquired disorder.<ref name="NINDS">{{cite web|title=NINDS Isaac's syndrome information page|url=http://www.ninds.nih.gov/disorders/isaacs_syndrome/isaacs_syndrome.htm|accessdate=8 May 2011|author=National Institute of Neurological Disorders and Stroke.|year=2010|archive-url=https://web.archive.org/web/20110412032703/http://www.ninds.nih.gov/disorders/isaacs_syndrome/isaacs_syndrome.htm|archive-date=12 April 2011|url-status=dead}}</ref> It is speculated that the [[plasma exchange]] causes an interference with the function of the [[voltage-dependent potassium channel]]s, one of the underlying issues of hyper-excitability in autoimmune neuromyotonia.<ref name="Arimura">{{cite journal|vauthors=Arimura K, Watanabe O, Katajima I, Suehara M, Minato S, Sonoda Y, Higuchi I, Takenaga S, Maruyama I, Osame M |title=Antibodies to potassium channels of PC12 in serum of Isaacs' Syndrome: Western blot and immunohistochemical studies|journal=Muscle Nerve|year=1997|volume=20|issue=3|pages=299–305 | doi=10.1002/(SICI)1097-4598(199703)20:3<299::AID-MUS6>3.0.CO;2-6|pmid=9052808}}</ref> Botox injections also provide short-term relief. Immunosuppressants such as Prednisone may provide long term relief for patients with some forms of the acquired disorder.
* Botox injections – Can provide short-term relief for severe spasms.
* Physical therapy – Helps maintain mobility and reduce muscle stiffness.


== Prognosis ==
== Prognosis ==
The long-term prognosis is uncertain, and has mostly to do with the underlying cause; i.e. autoimmune, paraneoplastic, etc. However, in recent years increased understanding of the basic mechanisms of NMT and autoimmunity has led to the development of novel treatment strategies. NMT disorders are now amenable to treatment and their prognoses are good. Many patients respond well to treatment, which usually provide significant relief of symptoms. Some cases of spontaneous remission have been noted, including Isaac's original two patients when followed up 14 years later.
Neuromyotonia is not fatal, and most patients respond well to treatment. However, symptoms can fluctuate, and early diagnosis improves long-term outcomes.


While NMT symptoms may fluctuate, they generally don't deteriorate into anything more serious, and with the correct treatment the symptoms are manageable.
Some cases may spontaneously remit, including Isaacs' original patients who recovered after 14 years. A small percentage of cases may progress to Morvan’s syndrome, which involves CNS symptoms like hallucinations and cognitive impairment.


A very small proportion of cases with NMT may develop central nervous system findings in their clinical course, causing a disorder called [[Morvan's syndrome]], and they may also have antibodies against potassium channels in their serum samples. [[Sleep disorder]] is only one of a variety of clinical conditions observed in Morvan's syndrome cases ranging from confusion and memory loss to [[hallucination]]s and [[delusion]]s. However, this is a separate disorder.
In paraneoplastic cases, prognosis depends on the underlying cancer type (often lung or thymus cancer).
 
Some studies have linked NMT with certain types of cancers, mostly lung and thymus, suggesting that NMT may be paraneoplastic in some cases. In these cases, the underlying cancer will determine prognosis. However, most examples of NMT are autoimmune and not associated with cancer.
 
== References ==
{{reflist}}


== External links ==
== External links ==
{{Medical resources
{{Medical resources
| DiseasesDB     = 31818
| DiseasesDB = 31818
| ICD10         = {{ICD10|G|71|1|g|70}}  
| ICD10 = {{ICD10|G|71|1|g|70}}
| ICD9           = {{ICD9|333.90}}  
| ICD9 = {{ICD9|333.90}}
| ICDO          =
| Orphanet = 11619
|  OMIM          =
|  MedlinePlus    =
|  eMedicineSubj  =
|  eMedicineTopic =
|  MeshID        = D020386
Orphanet       = 11619
}}
}}
{{stub}}
{{Diseases of myoneural junction and muscle}}
{{Diseases of myoneural junction and muscle}}
{{Channelopathy}}
{{Channelopathy}}
{{stub}}
[[Category:Rare diseases]]
[[Category:Rare diseases]]
[[Category:Myoneural junction and neuromuscular diseases]]
[[Category:Myoneural junction and neuromuscular diseases]]
{{No image}}

Latest revision as of 01:51, 20 March 2025

Rare neurological disorder affecting peripheral nerves



Neuromyotonia
Synonyms Isaacs' Syndrome
Pronounce N/A
Specialty N/A
Symptoms Muscle cramps, stiffness, fasciculations, hyperhidrosis, myoclonic jerks
Complications Morvan's syndrome (rare)
Onset Typically between ages 15–60
Duration Chronic, but treatable
Types N/A
Causes Autoimmune disease, paraneoplastic syndrome, genetic disorder
Risks N/A
Diagnosis Clinical evaluation, electromyography (EMG), antibody tests, CT scan
Differential diagnosis N/A
Prevention N/A
Treatment Anticonvulsants, plasma exchange, IVIg, immunosuppressants
Medication N/A
Prognosis Good with treatment
Frequency Rare (100–200 cases reported worldwide)<ref name="orpha">

Isaac syndrome(link). {{{website}}}. OrphaNet.



</ref>

Deaths N/A


Neuromyotonia (NMT), also known as Isaacs' Syndrome, is a rare neurological disorder characterized by peripheral nerve hyperexcitability, leading to continuous muscle activity. It results from repetitive motor unit action potentials of peripheral origin. The exact prevalence is unknown, but 100–200 cases have been reported worldwide.<ref name="orpha"/>

Signs and Symptoms[edit]

Neuromyotonia manifests as a diverse set of neuromuscular symptoms, including:

  • Muscle cramps and stiffness
  • Myotonia-like symptoms (slow muscle relaxation)
  • Walking difficulties
  • Hyperhidrosis (excessive sweating)
  • Myokymia (muscle quivering)
  • Fasciculations (muscle twitching)
  • Fatigue and exercise intolerance
  • Myoclonic jerks (sudden muscle movements)

Symptoms most commonly affect the calves, legs, trunk, and sometimes the face and neck, though other body parts may be involved. Symptom severity can range from mild discomfort to debilitating muscle activity. Up to one-third of patients also experience sensory disturbances.

Causes[edit]

Neuromyotonia is categorized into three types based on etiology: citation needed (November 2015)

  1. Acquired (most common, up to 80% of cases)
  2. Paraneoplastic (associated with certain cancers)
  3. Hereditary (genetic mutations)

The acquired form is believed to be autoimmune-mediated, typically involving antibodies targeting voltage-gated potassium channels (VGKCs) on motor nerves, leading to excessive nerve firing. NMT often coexists with other autoimmune diseases, such as:

Some cases improve with plasma exchange, suggesting an autoimmune basis. Onset generally occurs between ages 15–60, with most cases appearing before 40.<ref name="NINDS" />

Diagnosis[edit]

Diagnosis of neuromyotonia involves ruling out more common conditions and performing specialized neurological testing.

Clinical Evaluation

  • Neurological examination (strength, reflexes, coordination)
  • Blood tests for voltage-gated potassium channel (VGKC) antibodies
  • MRI and CT scans (to rule out tumors or other disorders)

Electromyography (EMG) and Nerve Conduction Studies (NCS) Neuromyotonia is characterized by:<ref name="Newsom-Davis">,

 Immunological associations of acquired neuromyotonia (Isaacs' syndrome), 
 Brain, 
 1993,
 Vol. 116(Issue: 2),
 pp. 453–469,
 DOI: 10.1093/brain/116.2.453,
 PMID: 8461975,</ref>
  • Continuous muscle fiber activity
  • Doublet, triplet, or multiplet single unit discharges
  • High-frequency bursts
  • Fibrillations and fasciculations

Because neuromyotonia is rare, misdiagnosis is common, often being confused with:

  • Amyotrophic lateral sclerosis (ALS) (especially in cases with fasciculations)<ref>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688–700.</ref>
  • Multiple sclerosis (MS)
  • Benign Fasciculation Syndrome (BFS) or Cramp Fasciculation Syndrome (CFS)

Types[edit]

There are three main types of neuromyotonia: citation needed (November 2015)

  • Chronic – Progressive but manageable with treatment.
  • Monophasic – Symptoms resolve within several years, often after infection or allergic reaction.
  • Relapsing-remitting – Periods of symptom flare-ups and remission.

Peripheral Nerve Hyperexcitability Spectrum Neuromyotonia is part of a spectrum of peripheral nerve hyperexcitability syndromes, which includes:<ref>,

 Phenotypic variants of autoimmune peripheral nerve hyperexcitability, 
 Brain, 
 2002,
 Vol. 125(Issue: 8),
 pp. 1887–1895,
 DOI: 10.1093/brain/awf178,
 PMID: 12135978,</ref>

1. Benign Fasciculation Syndrome (BFS) (mildest form) 2. Cramp Fasciculation Syndrome (CFS) 3. Neuromyotonia (NMT) 4. Morvan's syndrome (most severe, associated with hallucinations, memory loss, and insomnia)

Treatment[edit]

There is no known cure for neuromyotonia, but treatment can control symptoms.

First-Line Treatments

  • Anticonvulsants – Phenytoin and carbamazepine reduce nerve hyperactivity.
  • Plasma Exchange (Plasmapheresis) and IVIg – Effective in autoimmune cases.<ref name="NINDS">

National Institute of Neurological Disorders and Stroke.. NINDS Isaac's syndrome information page(link). {{{website}}}.




</ref>

  • Immunosuppressants – Prednisone or other corticosteroids help in autoimmune cases.

Other Therapies

  • Botox injections – Can provide short-term relief for severe spasms.
  • Physical therapy – Helps maintain mobility and reduce muscle stiffness.

Prognosis[edit]

Neuromyotonia is not fatal, and most patients respond well to treatment. However, symptoms can fluctuate, and early diagnosis improves long-term outcomes.

Some cases may spontaneously remit, including Isaacs' original patients who recovered after 14 years. A small percentage of cases may progress to Morvan’s syndrome, which involves CNS symptoms like hallucinations and cognitive impairment.

In paraneoplastic cases, prognosis depends on the underlying cancer type (often lung or thymus cancer).

External links[edit]



This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia